CTIC News Alert Cell Therapeutics (CTIC) 2.36 12/25/2014 12:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 2.36 $CTIC

First Week of CTIC February 2015 Options Trading
StockOptionsChannel.com - Wed Dec 24, 11:46AM CST
Investors in CTI BioPharma Corp saw new options become available this week, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new February 2015 contracts and...
CTIC: 2.36 (+0.05)

Insider Trading Alert - CTIC, FXCM And CRM Traded By Insiders
at The Street - Mon Dec 22, 9:45AM CST
Stocks with insider trader activity include CTIC, FXCM and CRM
FXCM: 16.88 (-0.12), CTIC: 2.36 (+0.05), CRM: 60.33 (-0.17)

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), NBIX: 21.33 (+0.09), GILD: 91.29 (+1.84), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), CTIC: 2.36 (+0.05), CEMP: 20.66 (+0.78), BMY: 59.15 (-0.01)

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 115.15 (+1.40), MYGN: 36.50 (+0.28), DNDN: 0.13 (-0.02), CTIC: 2.36 (+0.05), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Bone Degeneration - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/mtq3mr/bone_degeneration) has announced the addition of the "Bone Degeneration - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alethia Biotherapeutics Inc. - Calzada Limited - CTI BioPharma Corp. - GliaMed, Inc. - Histocell S.L. - TechnoPhage SA - TissueGene, Inc. For more information visit http://www.researchandmarkets.com/research/mt...generation
CTIC: 2.36 (+0.05)

Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.63 (-0.04), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), ONTX: 3.82 (+0.06), CTIC: 2.36 (+0.05), BMY: 59.15 (-0.01), STML: 15.53 (+0.23), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)

CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells
PR Newswire - Tue Dec 09, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays. The findings from this study were presented by Dr. Ceri Marrin, Consultant Haematologist, University Hospital of Wales at Cardiff University, during an oral presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9 in San Francisco, CA.
CTIC: 2.36 (+0.05)

Insider Trading Alert - CSU, IRBT And CTIC Traded By Insiders
at The Street - Mon Dec 08, 9:45AM CST
Stocks with insider trader activity include CSU, IRBT and CTIC
CSU: 25.08 (+0.10), CTIC: 2.36 (+0.05), IRBT: 34.94 (-0.11)

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/jtddt5/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - Gilead Sciences - Novartis - Nippon Shinyaku - CTI BioPharma - Incyte - Italfarmaco - Promedior - Pharma Mar For more information visit http://www.researchandmarkets.com/research/jt...lycythemia
GILD: 91.29 (+1.84), CTIC: 2.36 (+0.05), NVS: 93.91 (+0.66)

CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers
PR Newswire - Sat Dec 06, 11:00AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. Researchers presented the findings from this analysis at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9 in San Francisco, CA.
CTIC: 2.36 (+0.05)

CTI BioPharma earns $15M milestone
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:46AM CST

TEVA: 57.09 (+0.33), CTIC: 2.36 (+0.05)

CTI BioPharma awarded USD15m milestone payment for TRISENOX
M2 - Thu Dec 04, 6:25AM CST
Biopharmaceutical company CTI BioPharma (NASDAQ:CTIC)(MTA:CTIC) reported on Thursday the receipt of USD15m milestone payment from Teva Pharmaceutical Industries related to the achievement of sales milestones for TRISENOX (arsenic trioxide).
TEVA: 57.09 (+0.33), CTIC: 2.36 (+0.05)

CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX®
PR Newswire - Thu Dec 04, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $15 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI is eligible to receive up to an additional $80 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.
TEVA: 57.09 (+0.33), CTIC: 2.36 (+0.05)

Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
at The Street - Tue Dec 02, 10:00AM CST
Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
AGEN: 3.85 (unch), BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CYTR: 2.58 (+0.03), SNSS: 2.48 (-0.03), CTIC: 2.36 (+0.05), NVS: 93.91 (+0.66)

Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 6.99 (-0.03), VRTX: 115.15 (+1.40), NLNK: 39.08 (+1.36), IBIO: 0.68 (-0.04), CTIC: 2.36 (+0.05)

Why CTI BioPharma Corp. Stock Tumbled 10% in November
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 02, 7:41AM CST
CTIC data by YCharts What: Shares of CTI BioPharma , a biopharmaceutical company focused on developing therapies to treat cancer, tumbled 10% in November, based on data from S&P Capital IQ , following its issuance of convertible...
CTIC: 2.36 (+0.05)

Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dnbkc/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh - JW Pharmaceutical - Karyopharm - Kyowa Hakko Kirin - Les Laboratoires Servier - MacroGenics - Merck & Co - Millennium - Novartis - Piramal - Plexxikon - Polaris - Seattle Genetics - SpectraMab - Sunesis - Synta - Targa - Tolero - Verastem, For more information visit http://www.researchandmarkets.com/research/7d...tory_acute
MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), AMBI: 15.60 (+0.26), GSK: 42.85 (+0.11), CTIC: 2.36 (+0.05), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 33.00 (+0.34), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), CTIC: 2.36 (+0.05), GSK: 42.85 (+0.11), VSTM: 8.30 (+0.19), SNTA: 2.63 (+0.02), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), AMBI: 15.60 (+0.26), CELGZ: 3.34 (-0.01), KPTI: 37.78 (+1.28), NVS: 93.91 (+0.66)

CTI BioPharma Announces Data Presentations at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Dec 01, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.
CTIC: 2.36 (+0.05)

Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), BMY: 59.15 (-0.01), CTIC: 2.36 (+0.05), NVS: 93.91 (+0.66)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 46

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 97

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 57

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

CHITA LIVING Showcases Stylish Furniture at Nashville Event

Updated Category News Views 333

CHITA LIVING Celebrates Style and Comfort at Nashville Event HOUSTON, Oct. 28, 2024 -- CHITA LIVING, a distinctive furniture company renowned for its stylish and inviting designs, is thrilled to be a part of Modern Luxury Nashville's exciting Announcement Party, happening soon at Diamond Creek Farms. This event showcases the perfect blend of comfort and elegance, a true...

Continue Reading
Buffy Payne Joins LifeKnight as Chief Security Officer

Updated Category News Views 236

Buffy Payne Joins LifeKnight as Chief Security Officer Expanding Global Safety Innovation Through AI-Driven Detection and Direction LifeKnight, Inc., a leader in AI-powered safety and health monitoring technology, has appointed Buffy Payne as Chief Security Officer (CSO). Bringing over three decades of experience in corporate security and crisis management, her role...

Continue Reading
Host Hotels & Resorts Achieves Remarkable Sustainability Milestone

Updated Category News Views 187

Host Hotels & Resorts Recognized for Sustainability Efforts Host Hotels & Resorts, Inc. (NASDAQ: HST), a leading name in the lodging real estate investment trust (REIT) sector, has made headlines once again. The company proudly announced its inclusion in the Dow Jones Sustainability World Index for the sixth year in a row, solidifying its reputation as a global...

Continue Reading
Toll Brothers Unveils New Luxury Community at The Pinehills

Updated Category News Views 220

Luxury Living in The Pinehills Community In a significant development for homebuyers, Toll Brothers, Inc. (NYSE:TOL), recognized as the leading builder of luxury homes in the nation, is excited to announce the opening of the Broadleaf community at The Pinehills. This luxurious community, designed with the discerning homeowner in mind, offers breathtaking new construction...

Continue Reading
Watts Water Technologies Faces Challenges but Sees Potential Growth

Updated Category News Views 330

Watts Water Technologies Reports Third Quarter Earnings Watts Water Technologies, Inc. (NYSE: WTS), a leader in providing water solutions globally, has announced its third-quarter results, marked by a blend of challenges and prospects for strategic advancements. CEO Bob Pagano, alongside CFO Shashank Patel and Senior VP Diane McClintock, discussed the company’s mixed...

Continue Reading